Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Long-Acting Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1
NCT06336434Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabotegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by National Institute of Allergy and Infectious Diseases. Planned start May 2025; status: withdrawn.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06336434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336434.